These studies suggested CD133+ colon cancer cells from primary or metastatic tumors were equivalently resistant to oxaliplatin or Fas induced apoptosis, but this was reversed by inhibition of Fap1. The gene discussed is PROM1; the disease is metastatic neoplasm.